Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
New offering combines direct healthcare stakeholder input, therapeutic expertise, and AI-enabled execution to help life sciences organizations achieve faster insights. EXTON, PA – August 4, 2026 – Spherix Global Insights, a leading independent provider of market intelligence and advisory services for specialty pharmaceutical and biotech companies, today announced the launch
Nephrologists say they would nearly triple Xphozah use without access barriers, but Spherix chart data reveal that physicians substantially overestimate both phosphorus control and combination therapy use among their patients. EXTON, PA – July 29, 2026 – Access, not efficacy, stands between Ardelyx’s Xphozah® (tenapanor) and a materially larger share
Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as real-world experience grows. EXTON, PA – July 24, 2026 – The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime
Early physician experience suggests TYK2 inhibition may expand oral treatment options beyond traditional positioning, with implications for future competitive dynamics in psoriatic arthritis. EXTON, PA – July 23, 2026 — The launch of Bristol Myers Squibb’s Sotyktu® (deucravacitinib) is doing more than introducing another treatment option for psoriatic arthritis (PsA),
Key Takeaways A survey by Spherix Global Insights also finds that health plans and pharmacy benefit managers are using Medicare’s Maximum Fair Prices as benchmarks when negotiating discounts for drugs that were not selected for price negotiations. Health plans and pharmacy benefit managers are restructuring their benefit designs for both
Three-quarters of gastroenterologists and hepatologists report high unmet need for MASH therapies, while access to approved treatments remains limited. EXTON, PA, July 8, 2026 — The European market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a pivotal phase of development as increasing disease recognition converges with the recent approvals of
Parallel Spherix Global Insights studies reveal expanding biologic use and evolving treatment strategies have yet to fully translate into durable disease control and improved quality of life for many patients. EXTON, PA, July 7, 2026 — While the treatment landscape for systemic lupus erythematosus (SLE) continues to evolve with increasing
Originally published in Fierce Pharma Based on feedback from doctors, Novo Nordisk’s early success with the Wegovy pill may have been fueled in part by familiarity in the market with the GLP-1 compound. (Novo Nordisk) What’s been Novo Nordisk’s secret weapon to turn the tables on Eli Lilly and win
Only 15% of CTD-ILD patients achieve drug-free remission, fueling interest in Bristol Myers Squibb’s zola-cel, GSK’s Benlysta, and next-generation antifibrotics. EXTON, PA – June 17, 2026 – Despite the introduction of new therapies, connective tissue disease-associated interstitial lung disease (CTD-ILD) remains an area of significant unmet need, according to findings
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move earlier in treatment over time. EXTON, PA, June 12, 2026 — Despite widespread recognition that long-term steroid exposure should be minimized
Spherix Global Insights highlights rising enthusiasm for Priovant’s TYK2/JAK1 inhibitor alongside continued dissatisfaction with current treatment approaches in dermatomyositis and polymyositis. EXTON, PA — May 28, 2026 — Spherix Global Insights has released the 2026 update of Market Dynamix™: Idiopathic Inflammatory Myopathies (IIM), US, revealing a market increasingly poised for
Despite a more flexible administration profile, Foundayo generated lower first-month prescribing rates than the Wegovy Pill among both primary care physicians (PCPs) and endocrinologists. EXTON, PA, May 27, 2026 — As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients
Analysis of 187 audited patient charts reveals persistent operational barriers remain common for patients with large B-cell lymphoma (LBCL), reinforcing the role of targeted therapies during the CAR-T treatment journey EXTON, PA – May 21, 2026 – Despite growing adoption of CAR-T therapy in large B-cell lymphoma (LBCL), new findings
Despite incremental gains in awareness and prescribing, most launch metrics continue to trail recent rheumatology benchmarks, underscoring both the challenges and strategic importance of the first TYK2 inhibitor launch in rheumatology. EXTON, PA – May 19, 2026 – Data collected between May 4 and May 9, 2026 through Spherix Global
Nephrologists now prioritize SGLT2 inhibitors for kidney protection over glycemic control, while one-third report no perceived benefit of GLP-1s in CKD. Exton, PA – May 13, 2026 – Nephrologists are initiating SGLT2 inhibitors earlier in the chronic kidney disease (CKD) treatment journey and continuing them well below labeled eGFR thresholds.
Despite expanding biologic use, nearly 60% of lupus patients report high disease activity, while rising costs and treatment complexity continue to drive switching and discontinuation. EXTON, PA, May 5, 2026 — New findings from Spherix Global Insights’ Patient Voice Dynamix™: Systemic Lupus Erythematosus (SLE) 2026 highlight a market still defined
